
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gancyclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Human Hepatitis B Immunoglobulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Hannover Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins
Details : Hepatect (Human Hepatitis B Immunoglobulin) is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Hepatect
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Human Hepatitis B Immunoglobulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Hannover Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cytofulvin
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : University Hospital, Bordeaux
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cytotect (Cytofulvin) is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Kidney Transplantation.
Product Name : Cytotect
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 22, 2021
Lead Product(s) : Cytofulvin
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : University Hospital, Bordeaux
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Human Normal Immunoglobulin
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : RWTH Aachen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Human Normal Immunoglobulin is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Peritonitis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 07, 2017
Lead Product(s) : Human Normal Immunoglobulin
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : RWTH Aachen University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BT062
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BT062 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 12, 2012
Lead Product(s) : BT062
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
